Evidence map›Paper›PMID 42656439›Full record

ArticleFrontiers in endocrinology2026

Combination olaparib and cyclophosphamide cancer therapy exacerbates ovarian reserve depletion in mice with conditional loss of

Yujie Cao, Zaahida Abdul Jalil, Xinyi Mu, Jessica M Stringer, Nadeen Zerafa, Amy L Winship, Karla J Hutt

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yujie CaoWomen's Health and Ovarian Biology Laboratory, Biomedicine Discovery Institute, Department of Anatomy and Developmental Biology, Development and Stem Cells Program, Monash University, Clayton, VIC, Australia.
Zaahida Abdul JalilWomen's Health and Ovarian Biology Laboratory, Biomedicine Discovery Institute, Department of Anatomy and Developmental Biology, Development and Stem Cells Program, Monash University, Clayton, VIC, Australia.
Xinyi MuWomen's Health and Ovarian Biology Laboratory, Biomedicine Discovery Institute, Department of Anatomy and Developmental Biology, Development and Stem Cells Program, Monash University, Clayton, VIC, Australia.
Jessica M StringerWomen's Health and Ovarian Biology Laboratory, Biomedicine Discovery Institute, Department of Anatomy and Developmental Biology, Development and Stem Cells Program, Monash University, Clayton, VIC, Australia.
Nadeen ZerafaWomen's Health and Ovarian Biology Laboratory, Biomedicine Discovery Institute, Department of Anatomy and Developmental Biology, Development and Stem Cells Program, Monash University, Clayton, VIC, Australia.
Amy L WinshipWomen's Health and Ovarian Biology Laboratory, Biomedicine Discovery Institute, Department of Anatomy and Developmental Biology, Development and Stem Cells Program, Monash University, Clayton, VIC, Australia.
Karla J HuttWomen's Health and Ovarian Biology Laboratory, Biomedicine Discovery Institute, Department of Anatomy and Developmental Biology, Development and Stem Cells Program, Monash University, Clayton, VIC, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Olaparib, a small-molecule poly(ADP-ribose) polymerase (PARP) inhibitor, selectively impairs single-strand DNA repair and improves outcomes in patients with Methods: Adult wild-type (WT; Results: Ovarian reserve, endocrine function, estrous cyclicity, and IVF outcomes were assessed. Combination treatment did not affect serum AMH levels, estrous cyclicity, or IVF outcomes in either genotype, indicating no evidence of short-term impairment of reproductive function. Importantly though, Discussion: These findings demonstrate that BRCA1 deficiency may confer selective susceptibility of the ovarian reserve to combination chemotherapy and PARP inhibitor exposure without immediate impairment of endocrine or reproductive function. This study provides the first evidence that

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBRCA1 ProteinCyclophosphamideOocytesOvarian ReservePhthalazinesPiperazinesAnimalsFemaleMiceMice, KnockoutPoly(ADP-ribose) Polymerase InhibitorsBRCA1 ProteinBrca1 protein, mouseCyclophosphamideolaparibPhthalazinesPiperazinesPoly(ADP-ribose) Polymerase InhibitorsBRCA1 mutationcancer therapyfemale fertilityin vitro fertilizationovarian reserve

Identifiers

PMID42656439
PMCPMC13506483

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.